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Abstract In this study, we report the cloning of the rat cardiac 
isoform of calsequestrin on the basis of its interaction with an 
~protein kinase C-unique sequence (eV1) derived form the 
eprotein kinase C regulatory domain. Calsequestrin binds 
activated eprotein kinase C holoenzyme better than the inactive 
enzyme and nearly three times better than other protein kinase C 
isozymes. The interaction between Eprotein kinase C and 
calsequestrin is mediated by sequences in both the regulatory 
and kinase domains of the Eprotein kinase C. Finally, we show 
that calsequestrin is an eprotein kinase C substrate in vitro and 
protein kinase C phosphorylation of calsequestrin leads to a 
decreased binding of eprotein kinase C to calsequestrin. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
The sarcoplasmic reticulum (SR) of muscle cells is central 
to the excitation-contraction process as it stores calcium and 
therefore contributes to the regulation of intracellular calcium 
levels. However, the mechanisms responsible for mediating 
calcium release from the SR are not fully resolved. Calseques- 
trin (CS) is a moderate affinity (KD~ 1 raM; [1]), high ca- 
pacity (~40 mol CaZ+/mol CS, [2]) calcium binding protein 
present in the lumen of the cardiac SR. CS is thought o be a 
key component in the binding, storage and release of intra- 
cellular calcium (reviewed in [3]), not only due to its high 
calcium buffering but also due to its apparent association 
with the ryanodine receptor and other intra-SR proteins 
such as junctin and triadin [4,5]. Transgenic mice overexpress- 
ing cardiac CS exhibit cardiac hypertrophy and a lowered 
chronotropy, indicating that CS is important for the normal 
cardiac function at the level of the intact animal [6]. CS is also 
a substrate of caesin kinases I and II ([7,8]). Whereas phos- 
phorylation of skeletal muscle CS appears to influence the 
ryanodine receptor channel activity [9], the physiological ef- 
fects of caesin kinase phosphorylation upon cardiac CS re- 
main unclear. 
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The protein kinase C (PKC) family is a homologous group 
of at least 11 isozymes that regulate a wide array of cellular 
functions [10,11]. In cardiac tissue, these effects include both 
positive and negative inotropy [12,13], chronotropy [14] and 
other functions (reviewed in [15]). PKC phosphorylates multi- 
ple proteins in cardiac tissue at different cellular sites such as 
the myofibrillar elements [16,17] and the SR [18,19]. PKC 
activation in myocardial cells decreases calcium accumulation 
in the SR, which in part accounts for the negative inotropic 
response to PKC activation [20]. Despite current knowledge, 
PKC isozyme-specific activities have yet to be attributed to 
phosphorylation of specific cardiac substrates. 
Previous work has suggested that the regulatory domain 
of ePKC confers the specificity for this PKC isozyme in 
binding to both substrates [21] and non-substrate proteins 
[22,23]. Because unique sequences for ePKC lie within amino 
acids 1-142, the V1 region of ePKC (eV1), we and others 
[24] reasoned that at least a partial specificity for substrates 
is likely to reside within this region of the regulatory domain. 
We initially identified CS as a putative PKC binding protein 
via interaction cloning using recombinant eV1 as a probe of a 
rat cardiac myocyte cDNA expression library. We present 
here biochemical evidence that CS specifically interacts with 
PKC, preferentially with the e isozyme of PKC. We also 
demonstrate that CS is a substrate for ePKC in vitro and 
that phosphorylation of CS by EPKC inhibits its binding to 
CS. 
2. Materials and methods 
2.1. interaction chining of" CS and &olation of CS cDNA 
A Sprague-Dawley rat heart cDNA library was screened as de- 
scribed previously [22]. A detailed description of this method is pro- 
vided elsewhere [25]. The CS cDNA clone was excised in vivo with 
r408 helper phage from the pBluescript (Stratagene) phagemid cloning 
vector, sequenced and identified as the cardiac form of CS by 90.8% 
identity in a 360 amino acid overlap (SIM program on ExPASy 
WWW site, [26]) to the prototypical cardiac canine form of CS. 
This clone expresses all but the 51 N-terminal amino acids of rat 
cardiac CS according to a previously deposited sequence (accession 
number U332873. 
2.2. Expression of recombinant proteins 
The CS clone was amplified using PCR (with forward primer 
ATAGGCTTTGTGATGGTG and reverse primer TACCGAGCA- 
CAGTGCTGCTT), digested with EcoRI/BamHI and inserted behind 
the EcoRI/BamHl restriction sites on the maltose binding protein 
(MBP) expression vector pMAL-c2 (New England Biolabs), generat- 
ing a MBP fusion to CS (MBP-CS). This expression vector was trans- 
formed into an Escherichia coli TB1 host. The DNA fragment encod- 
ing eVI-FLAG was generated as previously described [22]. 
Overexpressed MBP fusion proteins were, where necessary, purified 
on an amylose affinity column (New England Biolabs), digested with 
bovine factor Xa (New England Biolabs) and, when necessary, further 
purified on a DEAE-cellulose column using a linear salt gradient. 
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2.3. PKC isozymes 
The bacculovirus expression vector encoding ePKC was obtained as 
a gift from Dr Robert Bell, Duke University. Insect Sf9 cells were 
infected with bacculovirus and harvested according to kit procedures 
provided by Stratagene. Where noted, purified human recombinant 
PKC isozymes produced in insect cells were purchased from Panvera. 
Mammalian PKC was partially purified from rat brain as previously 
described [27] to yield a mixed isozyme preparation of ~4.5 ~tg/ml 
total PKC with 5-9 U activity/ml relative to histone III-S (Sigma). 
2.4. Amylose column affl)Tity assay 
For each experimental sample, 300 pl (settled volume) of amylose- 
agarose resin (New England Biolabs) was washed in a Bio-Rad Poly- 
Prep chromatography column with 4 ml of a column wash buffer 
(20 mM Tris-HC1 pH 7.5, 0.2 M NaCI, 1 mM EDTA, 10 mM 
[~-mercaptoethanol). 50-500 p_g of total protein from the 14000×g 
supernatant of the appropriate MBP extract was loaded onto the 
column and washed with 20 ml column wash buffer. Columns were 
then plugged at the base, brought o a 1 ml total incubation volume 
with overlay buffer (0.2 M NaC1, 50 mM Tris-HC1 pH 7.5, 12 mM 
~-mercaptoethanol, 0.1% (w/v) BSA, 1% polyethylene glycol (7000 
MW average), 10 ~tg each of soybean trypsin inhibitor and leupeptin, 
20 ~tg/ml aprotinin and 10 mM phenylmethylsulfonyl fluoride) and 
incubated with partially purified rat brain PKC or SO-expressed re- 
combinant PKC isozymes in the presence or absence of activating co- 
factors (60 ~tg/ml phosphatidlyserine, 2 Jtg/ml diacylglycerol, 1 mM 
Ca 2+) or other reagents when noted. Incubations were carried out for 
30 min at room temperature with gentle agitation of the incubation 
slurry. Columns were then washed with 20 ml of wash buffer and the 
bound complex was eluted with 10 mM maltose in column wash 
buffer. Eluates were run on SDS-PAGE gels, transferred to nitrocel- 
lulose and subjected to Western blotting. Antibodies to 6- and ePKC 
(Gibco BRL) were used at a 1:300 dilution and antibodies to [3PKC 
(Seikagaku) were used at 1:500. Differences in binding were quanti- 
tated by assessing densitometric data obtained using a Galai ScanAr- 
ray II (Galai Instruments, Galai, Israel) imaging system from films 
exposed to either enhanced chemiluminescent light emission or auto- 
radiography. Quantitation was also obtained or verified by phosphor- 
imaging radioactivity or detection of enhanced chemifluorescent imag- 
ing of Western blots (Molecular Dynamics STORM 850, utilizing 
ImageQuant v 1.1). 
2.5. Kinase assay 
The ability of various PKC preparations to phosphorylate CS and 
histone III-S was assayed by following the incorporation of the [y- 
32phosphate] from ['/-32p]ATP into these substrates according to a 
method modified from that of Kikkawa et al. [28]. Specific protein 
phosphorylation was quantitated as described above (phosphorimag- 
ing) or the total protein phosphorylation was quantitated with liquid 
scintillation. 
2.6. lmmunoprecipitation q/' ePKC 
cPKC was isolated from the partially purified rat brain PKC prep- 
aration (see above) by incubating 5 ~tg anti-~PKC polyclonal rabbit 
IgG (Santa Cruz Biotech) with 0.5 ml of a 1:4 dilution (to ~ 1 ~tg/ml) 
of the PKC prep for 2 h at 4°C. IgG was then precipitated with 50 ~tl 
agarose-conjugated Protein G (Pharmacia) for 30 min at 4°C. 
3. Results 
3.1. Interaction cloning o f  CS 
We have postulated that the specificity of subcellular local- 
ization and function for each activated PKC isozyme is at 
least partly mediated by the binding of an isozyme to its 
specific receptor for activated C-kinase (RACK)  or RACKs  
[29,30]. We previously demonstrated that the VI region of 
ePKC (eV1) at least partly mediates the in vivo interaction 
between ePKC and proteins (including RACKs)  important for 
the EPKC function at RACK sites in cardiac myocytes [31,32]. 
We therefore chose to screen a rat cardiac cDNA expression 
library for proteins that interact'with eV1. This effort revealed 
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Fig. 1. The Vl-domain of ~PKC (~V1) binds CS in an affinity assay. 
Equimolar amounts of either recombinant MBP-CS or MBP were 
immobilized on amylose affinity columns. Immobilized proteins were 
then incubated with increasing amounts of FLAG-~V1-FLAG (~ 
3:1, molar ratio FLAG-eV1-FLAG:MBP-CS or MBP). After exten- 
sive washing, bound material was eluted with 10 mM maltose and 
the resultant eluates were subjected to Western blot analysis (anti- 
FLAG monoclonal antibodies). (A) A gel image that represents one 
of three independent experiments. (B) Graph data represent he 
mean + S.E.M. (n -> 3) of binding of FLAG-EV1-FLAG to MBP-CS 
(11) or MBP (O) relative to binding of FLAG-eV1-FLAG to MBP- 
CS at a 1:1 molar ratio. 
two independent clones, CS 2 and an gPKC-specific RACK 
[22]. 
The CS clone exhibits two putative PKC phosphorylat ion 
sites (MacVector analysis, Kodak-IBI)  using a RIKXS/TXRI  
K consensus and six putative PKC phosphorylat ion sites 
(PROSITE, ExPASy WWW site) using a S/TXR/K consensus 
search (Table 1). Of interest is the identity between the se- 
quences flanking two of these sites and the sequences flanking 
phosphorylated serines and threonines on the PKC substrates 
MARCKS [33,34] and troponin I [35] (Table 1). Our clone 
(AF001334) differs from a previously deposited sequence of 
rat cardiac CS (U33287) in two places. The first begins at 
residue 50 of AF001334 and differs in the first three amino 
acids most likely due to a cloning artifact. The second is at 
residues 208-211. AF001334 encodes S-208 and flanking se- 
quences identify this serine as a consensus PKC phosphoryl-  
at ion site. This residue is F-208 in U33287. However, the dog 
canine CS sequence (P12637) is identical to AF001334 in 208 
211 (Table 1). 
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Fig. 2. cPKC binds CS in an affinity assay. Assays were carried out as in Fig. 1, except hat incubations were performed in the presence of 
PKC with or without phospholipid (PL, 60 p_g/ml phosphatidylserine, 2 btg/ml diacylglycerol) activators, 1 mM CaC1 and free purified recombi- 
nant CS. (A) Recombinant cPKC (Panvera) binds to MBP-CS. Binding is specific to the CS portion of the MBP-CS fusion protein and binding 
is dependent upon PL activation of @KC. (B) Rat brain EPKC binds MBP-CS. This binding is inhibited with a 5-fold molar excess of free 
(non-immobilized) CS. Data are representative of three independent experiments. (C) Recombinant ePKC exhibits a higher binding activity to 
MBP-CS than I3IIPKC and 8PKC (all isozymes from Panvera). 150 ng of each PKC isozyme was incubated separately with constant (excess) 
amounts of immobilized MBP-CS (see Section 2) with 1 mM Ca 2+ and PL in duplicate over three independent experiments. Percentages of iso- 
zyme bound were determined based on quantitation of Western blots using a linear fit to densitometry of four internal standards of 25, 50, 100 
and 200 ng of each isozyme on the same blot as the eluates (values represent mean_+ S.E.M.). 
3.2. eV1 binds" CS in column a~ni O, assays 
We first confirmed the interaction of the EVI region (amino 
acids 2 142 of ePKC, lacking the pseudosubstrate site) with 
CS, employing an affinity binding assay independent of the 
original expression cloning method. CS was expressed and 
partially purified as a fusion protein to maltose binding pro- 
tein (MBP-CS). MBP-CS bound recombinant cV1 in a dose- 
dependent manner  (Fig. 1). Binding was specific to the CS 
port ion of the MBP-CS fusion protein, as eV1 did not interact 
significantly with MBP alone under the same molar dose-re- 
sponse range tested (Fig. 1B). MBP-CS bound as well or 
better to two cV1 degradation products of 14 and 20 kDa 
(Fig. 1), since Coomassie blue staining of the cV1 sample 
revealed that these fragments were about five and two times 
less abundant  han the full-length product, respectively (data 
not shown). N-terminal sequence analysis revealed that the 14 
kDa form comprises residues 27-142 of ePKC (Fig. 1). How- 
ever, no information is available on the 20 kDa fragment. The 
14 kDa fragment provides a direction for future studies to 
further map the CS binding site within eV1. 
3.3. ePKC binds CS in column affinity assays 
We next determined whether recombinant CS could bind 
cPKC holoenzyme in vitro and ascertained the conditions 
under which this binding occurs with respect o PKC activa- 
tion. MBP-CS bound @KC and this binding was enhanced 
upon phospholipid-induced activation of PKC (Figs. 2A, 3, 
5). The apparent affinity of rat brain EPKC for CS was further 
enhanced with 1 mM Ca 2+ (Fig. 2A). Since ePKC is a novel 
(Ca2+-independent) PKC isozyme, this result suggests that the 
calcium-loaded state of CS may influence its interaction with 
EPKC, as the KD of CS for Ca 2+ is about 1 mM [1]. Binding 
of cPKC to MBP-CS was specific to CS, since cPKC did not 
bind to MBP alone (Fig. 2A, B) and since free purified re- 
combinant CS competed with MBP-CS for PKC binding (Fig. 
2B). 
Phospholipid-activated recombinant ePKC. bound better to 
MBP-CS than either [31IPKC or 8PKC in vitro (Fig. 2C), 
which further supports the proposed preference of ePKC for 
interacting with CS. The observation that isozymes other than 
cPKC exhibit a binding activity to CS may indicate that part 
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Fig. 3. The pseudosubstrate peptide an  V1 compete with rat brain 
cPKC for binding to CS. Assays were carried out as in Fig. 2. (A) 
The pseudosubstrate p ptide (Gibco BRL) inhibits binding of cPKC 
to immobilized MBP-CS. Increasing amounts of peptide were co-in- 
cubated with PKC. Representative of three independent experi- 
ments. (B) eV1 competes with cPKC for binding to MPB-CS. The 
eV1 domain was co-incubated at a 2:1 molar ratio (eV1 :MBP-CS) 
with PL-activated PKC. Densitometry data, below, are the mean+ 
S.E.M. for three independent experiments normalized to binding in 
the absence of eV1. 
of the CS binding site on ePKC may lie within domains com- 
mon to the PKC isozymes. We also found that the binding of 
cPKC to MBP-CS decreased by 62+ 1.5% (mean+S.E.M.,  
n--3) in the presence of a 2-fold molar excess of cV1 (2:1 
cV1 :MBP-CS) and a saturating amount of cPKC (Fig. 3B). 
Thus, at least part of the CS binding site on ePKC lies within 
the VI region of the enzyme. 
To determine whether the interaction between CS and 
cPKC was also mediated via the active site of PKC, we meas- 
ured the ability of the PKC pseudosubstrate p ptide to inhibit 
CS binding to PKC. This peptide binds to the active site of 
the enzyme and is derived from the autoregulatory pseudo- 
substrate sequence (RFARKGALRQKNVHEVKN,  amino 
acid 19 36) of cPKC [36]. Pseudosubstrate peptide exhibited 
a dose-dependent inhibition on the interaction between CS 
and cPKC, with 50% inhibition occurring around 5 laM pep- 
tide (Fig. 3A), suggesting that this interaction is partly medi- 
ated by the active site of the enzyme. 
Although cV1 binding to CS occurs in the absence of lipids 
(suggestive of a direct protein-protein interaction), the re- 
quirement of lipid activators for ePKC holoenzyme binding 
to CS could reflect the presence of a lipid bridge between the 
proteins. However, the binding of PL-activated cPKC to 
MBP-CS was not attenuated when columns were washed 
with buffer containing 0.1% Triton X-100 prior to elution 
(data not shown). 
3.4. ePKC phosphorylates CS 
Upon identifying potential consensus phosphorylation sites 
on CS (Table 1), we determined whether CS is a PKC sub- 
strate. Recombinant ePKC phosphorylated CS in a phospho- 
lipid-dependent manner which was completely inhibited in the 
presence of 10 btM pseudosubstrate p ptide (Fig. 4A). CS was 
phosphorylated by rat brain PKC at a ratio of 3.01 +_ 0.18 tool 
Pi/mol CS (mean+ S.E.M., n = 3). Thus, of the six potential 
PKC phosphorylation sites on CS identified by consensus 
alignment (Table 1), at least three appear to be phosphoryl- 
ated by PKC in vitro. 
We next investigated the specificity of CS phosphorylation 
by cPKC since it has been suggested that cPKC has a sub- 
strate-specificity distinct fi'om other PKC isozymes [37,38]. 
Recombinant PKC (e, 13I and [3II isoforms overexpressed in
SO cells) exhibited little isozyme-specificity towards CS phos- 
phorylation (data not shown). While isozyme-specific phos- 
phorylation of PKC substrates in vitro has been difficult to 
establish [39], we nonetheless tested an alternative hypothesis. 
If CS is a superior substrate relative to other PKC substrates 
(e.g. histone), then, the cPKC activity toward CS should be 
greater than its activity toward histone when compared to 
other isozymes or group of isozymes. We thus purified 
ePKC from a rat brain mixed isozyme preparation by immu- 
noprecipitation and determined the ratios of specific activity 
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Fig. 4. ePKC phosphorylates CS. (A) Both SO-expressed ePKC and 
partially purified rat brain PKC phosphorylate CS. Reconabinantly 
expressed and purified CS was subjected to phosphorylation by 
these PKC sources for 10 min in the presence or absence of 240 btg/ 
ml phosphatidylserine (PS) and 8 Hg/ml diacylglycerol (DG) and 
10 gM pseudosubstrate p ptide. Autoradiographs follow the incor- 
poration of the y-phosphate of [y-32p]ATP. (B) Immunoprecipitated 
(IP) ePKC phosphorylates CS. Anti-ePKC polyclonal IgG bound to 
Protein G was used to isolate aPKC from a mixed isozyme rat 
brain PKC preparation. The r sultant IP or the immunodepleted 
(FT) PKC sample (containing c~, [3, 8, yPKC) were then used as ki- 
nase sources for phosphorylation of 1 ~M histone III-S and purified 
recombinant CS. The ratio of phosphorylation between the IP and 
the FT (IP:FT) is given as the mean + S.E.M. of three experiments. 
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Table 1 
Amino acid sequence alignment of rat cardiac CS (AF001334) cloned in this study with the prototypical canine cardiac muscle sequence 
(P12637) and the full sequence of rat cardiac CS (U33287). Alignment was performed with the aid of the MultiAlign sequence alignment pro- 
grain [49], utilizing the Blosum62 symbol comparison table with a gap weight of 12, a gap length weight of 2 and high and low consensus lev- 
els of 90 and 50%, respectively. 
1 50 
AF001334 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  A 
U33287 MKRIYLLVVG LYLLSFSRAE EGLNFPTYDG KDRVVSLSEK NLKQVLKRYD 
P12637 MKRTHLFIAG LYLLASCRAE EGLNFPTYDG KDRWSLTEK NFKQVLKKYD 
Consensus mkr . . l . . .g  ly l l . . . rae eglnfptydg kdrvvs l .ek  n .kqv lk .yd 
51 i00 
AF001334 RVCLYYHEPV SSDKVAQKQF QLKEIVLELV AQVLEHKNIG FVMVDSRKEA 
U33287 LLCLYYHEPV SSDKVAQKQF QLKEIVLELV AQVLEHKNIG FVMVDSRKEA 
P12637 VLCLYYHESV SSDKVAQKQF QLKEIVLELV AQVLEHKDIG FVMVDAKKEA 
Consensus . ICLYYHEpV SSDKVAQKQF QLKEIVLELV AQVLEHK#IG FVMVDsrKEA 
i01 150 
AF001334 KLAKRLGFSE EGSLYVLKGG RTIEFDGEFA ADVLVEFLLD L IEDPVEIVN 
U33287 KLAKRLGFSE EGSLYVLKGG RTIEFDGEFA ADVLVEFLLD L IEDPVE!VN 
P12637 KLAKKLGFDE EGSLYVLKGD RTIEFDGEFA ADVLVEFLLD L IEDPVEI IN 
Consensus KLAKrLGFsE EGSLYVLKGg RTIEFDGEFA ADVLVEFLLD L IEDPVEI !N 
151 200 
AF001334 NKLEVQAFER IEDQIKLLGF FKNEDSEYYK AFQEAAEHFQ PYIKFFATFD 
U33287 NKLEVQAFER IEDQIKLLGF FKNEDSEYYK AFQEAAEHFQ PYIKFFATFD 
P12637 SKLEVQAFER IEDQIKLIGF FKSEESEYYK AFEEAAEHFQ PYIKFFATFD 
Consensus nKLEVQAFER IEDQIKLIGF FKnE#SEYYK AF#EAAEHFQ PYIKFFATFD 
201 250 
AF001334 KGVAKKLSLK MNEVGFYEPF MDEPSVIPNK PYTEEELVEF VKEHQRP~LR 
U33287 KGVAKKLFLE VNEVGFYEPF MDEPSVIPNK PYTEEELVEF VKEHQRPTLR 
P12637 KGVAKKLSLK MNEVDFYEPF MDEPIAIPDK PYTEEELVEF VKEHQRPTLR 
Consensus KGVAKKLsLk mNEVgFYEPF MDEPsvIP#K PYTEEELVEF VKEHQRPTLR 
251 300 
AF001334 PLRPEDMFET WEDDLNGIHI  VAFAEKSDPD GYEFLEILKQ VARDNTDNPD 
U33287 PLRPEDMFET WEDDLNGIHI  VAFAEKSDPD GYEFLEILKQ VARDNTDNPD 
P12637 RLRPEDMFET WEDDLNGIHI  VAFAERSDPD GYEFLEILKQ VARDNTDNPD 
Consensus rLRPEDMFET WEDDLNGIHI  VAFAEkSDPD GYEFLEILKQ VARDNTDNPD 
301 350 
AF001334 LSILWIDPDD FPLLVAYWEK TFKIDLFKPQ IGVVNVTDAD SVWMEIPDDD 
U33287 LSILWIDPDD FPLLVAYWEK TFKIDLFKPQ IGVVNVTDAD SVWMEIPDDD 
P12637 LSIVWIDPDD FPLLVAYWEK TFKIDLFKPQ IGVVNVTDAD SVWMEIPDDD 
Consensus LS I IWIDPDD FPLLVA%WEK TFKIDLFKPQ IGVVNVTDAD SVWMEIPDDD 
351 400 
AF001334 DLPTAEELED WIEDVLSGKI  NTEDDDNEDE DDDGDNDNDD DDDDDDNSDE 
U33287 DLPTAEELED WIEDVLSGKI  NTEDDDNEDE DDDGDNDNDD DDDDDDNSDE 
P12637 DLPTAEELED WIEDVLSGKI  NTEDDDNE.E GDDGDDDEDD DDDDGNNSDE 
Consensus DLPTAEELED WIEDVLSGKI  NTEDDDNEdE dDDGD#D#DD DDDd#NSDE 
401 413 
AF001334 DNDDSDDDDD DDE 
U33287 DNDDSDDDDD DDE 
P12637 ESNDDSDDDD E.. 
Consensus #n#DsdDDDD #de 
Consensus PKC phosphory lat ion  site al ignment: 
AF001334 246-251 RP~LRR 
AF001334 320-323 KTFK 
MARCKS KSFK 
troponin I RPTLRR 
Consensus ymbols are as follows: ! is any one of (l, V); $ is any one of (L, M); % is any one of (F, Y); # is any one of (N, D, Q, E, B, Z). 
PROS1TE consensus phosphorylation residues in AF001334 are noted in bold underscore (S, T). 
of the ePKC immunoprecipitate (IP) to the total remaining 
PKC in the flow-through (FT, containing c~, [31, [3II, ~ and 
7PKC isozymes) relative to both CS and histone III-S. We 
found that this ratio (IP:FT) was 3-fold higher for purified 
CS than for histone III-S (Fig. 4B), suggesting that ePKC 
phosphorylates CS three times better than histone IH-S. 
This is noteworthy since the mixed isozyme PKC preparation 
was originally purified on the basis of activity toward histone 
III-S. These data indicate that CS may be a preferred ePKC 
substrate in vitro. 
3.5. PhosphotTlation of CS by PKC disrupts their association 
If CS is a PKC substrate, then, PKC should not bind as 
well to PKC-phosphorylated CS as the unphosphorylated 
form of CS, as seen for other PKC binding proteins which 
are substrates [40]. Binding assays were carried out on immo- 
bilized MBP-CS in the presence of 20-100 gM ATP and 
20 mM Mg 2+. After phosphorylation, the amount of bound 
~PKC decreased by 72_+ 6.4% (average +S.E.M., n = 4) (Fig. 
5, lanes 1 versus 4, 5). PKC in this eluate (incubated with 
ATP) also underwent autophosphorylation as evidenced by 
an upward band shift. These columns were then washed and 
the phosphorylated CS immobilized on the column was incu- 
bated with fresh PKC in the absence of ATP/Mg 2+. We ob- 
served that MBP-CS, once phosphorylated byPKC, lost bind- 
ing for additional ePKC by 62+ 10% (n=4) in ATP-free 
M.M. Rodriguez et al./FEBS Letters 454 (1999) 240~46 245 
Lane # 1 2 3 4 5 6 7 
Incubation round 
~PKC 
Round l: 
PL 
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ATP (~tM) 
Round 2: 
PL 
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ATP 
l 1 
÷ 
÷ 
1 112  2 
÷ ÷ ÷ 
O0 20 100 
÷ ÷ 
Fig. 5. Phosphorylation of CS inhibits binding of rat brain ePKC 
and attenuates subsequent re-association f ~PKC in the absence of 
ATP. Equimolar amounts of MBP-CS were immobilized as in Fig. 
1 and subjected to PKC binding and/or phosphorylation. PKC acti- 
vation was performed with a phospholipid (PL) preparation of 
60 gg/ml phosphatidylserine (PS) and 2 gg/ml diacylglycerol (DG). 
Lanes 1, 2 and 3 represent ~PKC eluted with the MBP-CS fusion 
after incubation with PL, PL+10 mM EGTA and 10 mM EGTA, 
respectively. Lanes 4 and 5 represent ePKC eluted with the MBP- 
CS fusion protein after PKC phosphorylation (incubation with PL 
and 20 and 100 gM ATP, respectively). Lanes 6 and 7 represent 
columns prepared identically to those in lanes 4 and 5, respectively, 
followed by a buffer wash and re-incubation with fresh PKC and 
PL under non-phosphorylating conditions. 
ing for transient exposure (and thus possibly phosphorylation) 
of the nascent polypeptide chain to the cytosol [48]. In either 
case, phosphorylation of CS is likely to alter the calcium 
homeostasis regulated by this major calcium binding protein 
in the heart [9]. 
We have described what will likely be a useful approach 
toward identifying PKC isozyme-specific binding proteins 
which also act as PKC substrates. Utilizing this method, we 
find that the cardiac isoform of CS appears to be an ePKC- 
selective binding protein and substrate. The in vitro character- 
ization of the interaction between ~PKC and CS suggests that 
CS may be a member of a distinct class of PKC substrates 
which bind to PKC in an isozyme-selective manner by inter- 
action with both variable (isozyme-unique) domain(s) and the 
catalytic site of the enzyme. Thus, in vivo, CS may be phos- 
phorylated preferentially by ePKC over other PKC isozymes 
due to binding properties contributed by the ePKC-unique 
region, eV1. 
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